Zydus Lifesciences moves up as its venture capital arm invests in Illexcor Therapeutics
Zydus Lifesciences is currently trading at Rs. 893.25, up by 4.25 points or 0.48% from its previous closing of Rs. 889.00 on the BSE.
The scrip opened at Rs. 893.30 and has touched a high and low of Rs. 897.20 and Rs. 885.60 respectively. So far 3143 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1323.90 on 09-Aug-2024 and a 52 week low of Rs. 859.15 on 04-Mar-2025.
Last one week high and low of the scrip stood at Rs. 917.25 and Rs. 872.30 respectively. The current market cap of the company is Rs. 89514.58 crore.
The promoters holding in the company stood at 74.98%, while Institutions and Non-Institutions held 18.18% and 6.84% respectively.
Zynext Ventures USA LLC (Zynext Ventures), the venture capital arm of Zydus Lifesciences (Zydus), has invested in Illexcor Therapeutics (Illexcor), a pioneering biopharmaceutical company developing next-generation oral therapies for sickle cell disease (SCD). This investment underscores Zynext Ventures' commitment to supporting disruptive healthcare innovations that address significant unmet medical needs.
Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD. Their lead asset, currently in preclinical development, is designed to bind to Hemoglobin S and effectively block polymerization and sickling, offering the potential for disease-modifying clinical benefits.
Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.
